Targeting CD137 enhances the efficacy of cetuximab

Holbrook E. Kohrt, … , John Sunwoo, Ronald Levy

*J Clin Invest.* 2019;129(6):2595-2595. [https://doi.org/10.1172/JCI129689](https://doi.org/10.1172/JCI129689).

Retraction

Original citation: *J Clin Invest.* 2014;124(6):2668–2682. [https://doi.org/10.1172/JCI73014](https://doi.org/10.1172/JCI73014)

Citation for this retraction: *J Clin Invest.* 2019;129(6):2595. [https://doi.org/10.1172/JCI129689](https://doi.org/10.1172/JCI129689)

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Find the latest version:

[http://jci.me/129689/pdf](http://jci.me/129689/pdf)
Retraction

**Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer**


Citation for this retraction: *J Clin Invest*. 2019;129(6):2595. https://doi.org/10.1172/JCI129688.

Stanford University School of Medicine recently notified the *JCI* of concerns regarding Figure 4, A and C, and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the *JCI* is retracting this article.

**Retraction**

**Targeting CD137 enhances the efficacy of cetuximab**


Citation for this retraction: *J Clin Invest*. 2019;129(6):2595. https://doi.org/10.1172/JCI129689.

Stanford University School of Medicine recently notified the *JCI* of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the *JCI* is retracting this article.